F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022
F-star Therapeutics, a clinical-stage biopharmaceutical firm, is set to hold a conference call on May 10, 2022, at 9:00 a.m. EST to discuss its first quarter 2022 financial results and corporate updates. Investors can join via a live webcast or by phone. The company focuses on next-generation immunotherapies, utilizing tetravalent bispecific antibodies to advance cancer treatment. With over 500 patents related to its innovative antibody discovery platform, F-star is engaged in partnerships targeting critical unmet medical needs in oncology and beyond.
- Company has four second-generation immuno-oncology therapeutics in clinical trials.
- Holds over 500 granted patents and pending applications related to its technology.
- Attracting partnerships with biopharma companies for innovative cancer therapies.
- None.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the Company will hold a conference call and webcast on May 10th, 2022, at 9:00 a.m. EST to review first quarter 2022 financial results and provide a corporate update.
To access the call, participants may join via a live webcast on the Investors & News section of the F-star Therapeutics website, under Events and Presentations. To join by phone, participants may dial the following numbers at least 10 minutes prior to the start of the call:
| Investors dial | 1-877-704-4453 |
| International investors dial | 1-201-389-0920 |
| Webcast | Link |
| Conference ID | 13728991 |
A replay of the conference call will be available for 90 days from the call and may be accessed in the Investor & News/Events and Presentations section of the F-star Therapeutics website.
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.
For more information visit our website and follow us on LinkedIn and Twitter.
For further information, please contact:
For investor inquiries:
John Fraunces
Relationship Manager
+1 917-355-2395
jfraunces@lifesciadvisors.com
For media inquiries:
Helen Shik
Shik Communications LLC
+1 617-510-4373
helen@shikcommunications.com
FAQ
When will F-star Therapeutics hold its next conference call?
What will F-star Therapeutics discuss during the conference call?
How can investors access the F-star Therapeutics conference call?
What is the ticker symbol for F-star Therapeutics?
What type of therapies is F-star Therapeutics developing?
